Neuroepithelial neoplasm

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This study tests a new drug called LMP744 in people whose glioblastoma has come back after standard treatment. The drug is designed to kill cancer cells by blocking a key growth signal and interfering with DNA repair. Participants will receive the drug through a vein for 5 days e…

This early-phase trial at Mayo Clinic is testing combinations of four drugs (dasatinib, quercetin, fisetin, and temozolomide) in 30 adults with previously treated glioma that still has residual tumor cells. The goal is to see if it's feasible to use individual patient data from b…

This early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …

This study tests whether adding the drug dinutuximab to standard chemotherapy and other treatments helps children with high-risk neuroblastoma live longer without their cancer returning. About 478 children and young adults up to age 30 will be randomly assigned to receive either …

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This Phase III trial is testing whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of brain tumor (IDH-mutated grade 3 astrocytoma). About 408 participants will receive either vorasidenib or a pla…

This study tests the drug abemaciclib, typically used for cancer, in people with neurofibromatosis type 1 (NF1) who have atypical neurofibromas that cannot be surgically removed. The goal is to find a safe dose and see if it can shrink or stabilize these tumors. Participants take…

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This early-phase study is testing the safety and how the body handles a drug called tovorafenib in Japanese children, teens, and young adults with a type of brain tumor (low-grade glioma) that has a specific genetic change (BRAF alteration) and has come back or is growing. Six pa…

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This phase 2 trial tests whether adding DOC1021, a personalized dendritic cell vaccine, to standard treatment (surgery, chemo, radiation) improves survival in adults newly diagnosed with glioblastoma. About 180 participants will be randomly assigned to receive the vaccine plus st…

This Phase 3 trial tests a device called SonoCloud-9, which uses ultrasound to temporarily open the blood-brain barrier, allowing more carboplatin chemotherapy to reach glioblastoma tumors that have returned after initial treatment. About 560 participants will be randomly assigne…

This phase II trial is testing whether adding the drug naxitamab (Danyelza) to standard chemotherapy improves outcomes for children newly diagnosed with high-risk neuroblastoma. About 93 participants will receive naxitamab during five cycles of induction chemo. The goal is to see…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…

This early-stage trial tests a personalized cell therapy for children with recurrent neuroblastoma or newly diagnosed DIPG, two aggressive cancers. The treatment uses the child's own immune cells (dendritic cells and T cells) and stem cells, trained to attack their specific tumor…

The DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This study tests whether adding an antibody drug called hu14.18K322A to standard chemotherapy helps children with high-risk neuroblastoma, a rare but aggressive childhood cancer. About 144 children and teens aged 18 months to 18 years will receive the combination over up to 12 cy…

This study tests whether a bivalent vaccine, taken with a sugar called beta-glucan and a protein (GM-CSF), can help prevent high-risk neuroblastoma from returning in children who are currently in remission. The treatment works by training the immune system to recognize and attack…

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This study looks at how safe and effective temozolomide (brand name Amitzo) is for people with aggressive brain tumors (grade III and IV gliomas). Researchers are tracking 100 patients to see how often liver injury occurs and to monitor other side effects. The goal is to better u…

This study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This study tracks how well the drug Koselugo (selumetinib) works and what side effects it causes in people with Neurofibromatosis Type 1 and painful nerve tumors. About 200 patients in South Korea will be followed during their normal doctor visits. The goal is to confirm the drug…

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…

This phase II trial tests whether vortioxetine, a drug currently used for depression, can help people with newly diagnosed glioblastoma. The study will enroll 78 adults and measure if the drug extends the time before the cancer worsens. Vortioxetine was selected because lab tests…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This phase 1 trial tests a new type of immunotherapy for people with recurrent or progressive high-grade gliomas, including glioblastoma. The treatment uses the patient's own T cells, which are genetically modified in the lab to target a protein called IL13Rα2 found on tumor cell…

This early-phase study tests the drug lorlatinib in children and young adults (ages 1 to 21) with newly diagnosed high-grade glioma, a fast-growing brain tumor, that has a specific genetic change (ALK or ROS1 fusion). The goal is to see if the drug can shrink or control the tumor…

This study tests a drug called zotiraciclib in people with a certain type of brain tumor (glioma) that has come back after treatment. The tumor must have a specific gene mutation (IDH1 or IDH2). Participants take the drug by mouth in cycles. The goal is to see if the drug can slo…

This study tests a new drug, BAY 3713372, for people with solid tumors that have a specific genetic deletion called MTAP. The drug is designed to kill cancer cells while sparing normal cells. The trial will first find a safe dose, then test how well it works in up to 450 particip…

This large international trial is testing several different drugs, including temozolomide, lomustine, regorafenib, and paxalisib, in people with newly diagnosed or recurrent glioblastoma, an aggressive brain cancer. The study uses an adaptive design, meaning it can quickly drop i…

This early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This phase 2 trial is testing whether combining the drug ONC201 with other treatments (like paxalisib or a cancer-killing virus called DNX-2401) can help children and young adults with diffuse midline gliomas, a rare and aggressive brain cancer. The study enrolls 360 participants…

This study tests two drugs—retifanlimab (an immunotherapy) and DFMO (a growth blocker)—alone or together in 33 adults with progressive high-grade glioma, an aggressive brain cancer. The goal is to find the safest, most effective dose and see if the combination boosts the immune s…

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This study is for adults with recurrent glioblastoma, an aggressive brain cancer. It tests whether adding a precise type of radiation (stereotactic radiosurgery guided by a special PET scan) to a device that delivers electric fields to the brain (TTFields) helps people live longe…

This early-phase trial tests a new way to give radiation to people whose glioblastoma (a severe brain cancer) has come back after initial treatment. About 28 adults will receive focused radiation over 1 to 3 weeks, with different schedules to find the safest dose. The goal is to …

This early-phase trial is testing a new drug called M3554, which is designed to seek out and attack cancer cells that have a protein called GD2 on their surface. The study will include up to 52 people with advanced soft tissue sarcoma or glioblastoma that has not responded to pri…

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…

This first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This early-stage trial is testing whether specially engineered immune cells (called CAR-T and CTL cells) and a dendritic cell vaccine can safely treat people with neurofibromatosis or schwannomatosis, conditions that cause nerve tumors. The study will enroll 100 participants aged…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This early-phase trial tests a drug called BMS-986504 in up to 12 people with recurrent glioblastoma, a severe brain cancer. The drug targets tumors with a specific genetic change (MTAP loss). The study first checks if the drug can reach the brain tumor during surgery, then looks…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This study tests an experimental treatment for glioblastoma, a serious brain cancer. It combines a drug (5-ALA) with a special ultrasound device that aims to target cancer cells without surgery. About 103 people who have completed standard therapy will be randomly assigned to get…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This phase 2 trial tests whether sitagliptin, a diabetes drug, can improve the immune system's ability to attack glioblastoma, an aggressive brain tumor. The study will enroll 48 adults with grade 4 glioma who are scheduled for surgery. Some participants will receive sitagliptin …

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This phase II trial tests whether an intensified treatment plan can delay tumor growth in adults with high-risk glioblastoma that was only partially removed or came back quickly. Participants receive higher radiation doses to the remaining tumor, plus chemotherapy and two immunot…

This early-phase trial tests an experimental drug called RSC-1255, given alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The study has two parts: first, finding a safe dose, and …

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This early-stage study tests a combination of antiretroviral drugs (normally used for HIV) and a laser procedure to treat high-grade gliomas—aggressive brain tumors that cannot be surgically removed. About 24 adults with newly diagnosed tumors will receive the laser treatment fol…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This early-phase trial tests a personalized RNA vaccine made from each patient's own tumor. It aims to teach the immune system to attack the cancer. The study includes adults with glioblastoma and children with high-grade gliomas or medulloblastoma. The main goals are to see if t…

This early-stage trial tests a drug called 5-ALA, already used during brain tumor surgery, combined with radiotherapy for people whose glioblastoma has returned. The main goal is to find the safest dose and schedule of this combination. About 34 participants will be enrolled to s…

This early study tests a device called TheraSphere GBM in 36 people whose glioblastoma has come back after prior treatment. The device delivers tiny radioactive beads directly to the tumor to try to control it. The main goal is to check if the procedure is safe, not yet whether i…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This Phase 2 trial tests whether adding the experimental drug silevertinib to standard chemotherapy (temozolomide) helps people with a specific type of newly diagnosed glioblastoma live longer without their cancer worsening. The study includes 162 participants whose tumors have c…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study tests two experimental drugs, CTX-009 and CTX-471, in people whose glioblastoma has returned after standard treatment. The goal is to see if these drugs are safe and can help control the tumor or extend survival. About 54 participants will receive either CTX-009 alone …

This clinical trial tests a new type of immunotherapy called 4SCAR-T, which uses a patient's own immune cells engineered to recognize and attack three different markers (GD2, PSMA, and CD276) on neuroblastoma cancer cells. The study enrolls children and adults (ages 1 to 65) with…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safe…

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every t…

This early-phase study tests a new drug called BG-C137, which delivers chemotherapy directly to cancer cells that have a specific marker (FGFR2b). The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have run out of standard options. Abo…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-stage trial is testing the safety and best dose of two drugs, trametinib and everolimus, given together to children and young adults whose gliomas (a type of brain tumor) have come back after previous treatment. The study aims to find the highest dose that is safe and …

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This study tests a combination of a vaccine targeting the CMV virus (PEP-CMV) and an immunotherapy drug (nivolumab) in children and young adults with certain aggressive brain tumors, including diffuse midline glioma and medulloblastoma. The goal is to see if this approach is safe…

This early-stage trial tests whether personalized immune cells (T-cells) can safely treat young children with aggressive brain tumors. The T-cells are designed to attack unique markers found on each child's tumor. Up to 12 children under 5 with embryonal brain tumors or recurrent…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This study tests a new way to give proton radiation to children with low-grade glioma, a common brain tumor. The goal is to avoid the hippocampus, a brain area key for memory, to reduce long-term memory loss. About 74 children will receive this targeted radiation, and researchers…

This phase 2 trial tests the drug erdafitinib in 30 adults with a specific type of brain tumor (IDH-wild type glioma) that has come back or is getting worse. The tumor must have a certain gene fusion (FGFR-TACC). Erdafitinib blocks a faulty protein that helps cancer cells grow. T…

This early-phase trial is testing a new radioactive drug, [177Lu]Lu-DOTA-EB-RGD2, in 24 patients with recurrent high-grade glioma, a fast-growing brain cancer. The drug is designed to seek out and deliver radiation directly to tumor blood vessels. It can be given through a vein o…

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This study tests whether a targeted drug called selumetinib works as well as standard chemotherapy (carboplatin and vincristine) for children and young adults with a slow-growing brain tumor called low-grade glioma. Participants must be 2 to 21 years old and have a tumor without …

This study tests methimazole, a drug normally used for thyroid problems, in people with progressive glioblastoma (a fast-growing brain tumor). Researchers want to see if it can help control the disease and how safe it is. About 19 adults will receive different doses to find the b…

This early-phase trial is testing whether sitagliptin, a drug used for diabetes, can help treat recurrent grade 4 glioma (a severe brain cancer) when combined with the standard drug bevacizumab. The study involves 45 adults whose cancer has returned after initial treatment. Resea…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This trial tests a drug called selinexor combined with standard radiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) that has a specific genetic change (H3 K27M mutation). The study has two parts: first, fi…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …

This study tests a new drug called PEEL-224, alone or with standard chemotherapy, in children and young adults whose solid tumors have not responded to treatment or have returned. The first part finds the safest dose, and the second part measures how well the drug combination shr…

This early-phase study tests the safety of delivering the chemotherapy drug topotecan directly to the brain using a pump and catheter system (convection-enhanced delivery) in 6 people with a recurrent, aggressive type of brain tumor called IDH-mutant malignant glioma. The treatme…

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This study is testing a new way to treat glioblastoma, an aggressive brain cancer that has come back after initial treatment. Doctors will place tiny devices that release a special type of radiation directly into the tumor. The goal is to see if this approach is safe and possible…

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This early-phase trial tests a single dose of a radioactive drug called [177Lu]Lu-XT771 in people with recurrent glioblastoma, an aggressive brain cancer. The drug is injected directly into the cavity left after tumor removal surgery, aiming to deliver radiation precisely to canc…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This early-stage trial tests a new combination treatment for children and young adults (ages 3-39) with recurrent malignant brain tumors that can be surgically removed. The treatment uses two genetically modified viruses injected into the tumor site, plus an oral anti-herpes drug…

This study looks at whether patients with a certain type of slow-growing brain tumor (low-grade glioma with a BRAF V600 mutation) can safely stop or reduce their dose of two targeted drugs, dabrafenib and trametinib, after 12-24 months of treatment. About 96 participants will eit…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study tests whether metformin, a common diabetes medicine, can help children and young adults with a rare brain tumor called PFA ependymoma that has come back. About 30 participants will take metformin and have surgery and imaging to see if the drug changes certain proteins …

This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …

This early-phase trial tests the safety of a new treatment for people with recurrent or progressive high-grade glioma, a serious brain cancer. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into t…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This study tests a cancer vaccine for people with newly diagnosed glioblastoma, a serious brain cancer. The vaccine is designed to help the immune system attack tumor cells. About 35 participants will receive the vaccine after standard treatment. The goal is to see if it is safe …

This study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…

This early-phase trial tests a new drug called ONC206 in children and young adults with diffuse midline glioma or other recurrent brain tumors. The drug aims to kill cancer cells by causing stress in them, without harming healthy cells. Researchers are looking for the safest dose…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…

This study tests a combination of two drugs, mirdametinib (taken by mouth) and vinblastine (given through a vein), in children and young adults with a type of brain tumor called low-grade glioma that has a specific genetic change (MAPK pathway activation). The trial has three par…

This early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…

This early-phase trial tests two experimental drugs, ABBV-637 and ABBV-155, alone or together with ERAS-801 in people whose glioblastoma has come back after standard treatment. About 60 adults with a specific genetic marker (EGFR amplification) will take part. The main goal is to…

This early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…

This phase 2 trial tests a new approach for children and young adults with relapsed or hard-to-treat neuroblastoma. Patients receive donor immune cells (NK cells) along with standard chemotherapy and an antibody therapy. The goal is to see if this combination can shrink tumors or…

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…

This study tests a new drug (Debio 0123) combined with standard chemotherapy (temozolomide) and sometimes radiation in adults with glioblastoma, an aggressive brain cancer. The goal is to find the safest dose and see if the combination helps people live longer. About 116 particip…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…

This early-phase trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and cabozantinib (a targeted therapy)—in patients whose glioblastoma has returned after standard treatment. The goal is to see if the combination is safe and can help control the cancer. …

This early-phase study tests whether dapagliflozin, a diabetes medicine, is safe for children with brain or solid tumors that have come back or not responded to other treatments. About 20 children will receive the drug alongside standard care. The goal is to check for side effect…

This trial tests a new gene therapy called TGX-007 for people with a fast-growing brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two special instructions: one helps a common drug kill cancer cells, and the other wakes up the immune system to attack…

This early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…

This pilot study tests whether adding APG-157 (a pastille dissolved in the mouth) to standard bevacizumab can help people with recurrent high-grade glioma. About 30 participants will take APG-157 three times daily while continuing bevacizumab. The study tracks survival, tumor res…

This phase 2 trial tests whether specially trained donor immune cells, called CIML-NK cells, can be safely given to 20 children and young adults (ages 1-39) with relapsed or refractory neuroblastoma. The cells are made from a half-matched donor and infused alongside standard dinu…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This program provides gallium maltolate (GaM) to adults aged 18 and older with glioblastoma that has returned or is not responding to standard treatments. The goal is to offer a possible treatment option when no others are available. Patients must be able to swallow capsules and …

This study tests whether adding a second round of radiation to the chemotherapy drug lomustine helps people with recurrent glioblastoma live longer. About 411 adults whose brain tumor has returned after standard treatment will be randomly assigned to get lomustine alone or lomust…

This early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find th…

This early-phase study tests whether adding chemotherapy directly into the spinal fluid (intrathecal topotecan) followed by maintenance pills is feasible for children under 6 with high-risk embryonal brain tumors. About 15 children will receive this treatment after standard high-…

This early-stage trial tests an oral drug called GLIX1 in 30 adults with recurrent or progressive high-grade glioma, a fast-growing brain cancer. The study aims to find the safest dose and check for any signs of tumor control. Participants take the drug daily until their disease …

This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…

This early-phase trial tests a combination of two drugs—D2C7-IT and 2141-V11—for adults with recurrent malignant glioma, a serious brain cancer. The drugs are delivered directly into the tumor and nearby lymph areas. The main goal is to check safety and find the right dose in 90 …

This study tests a drug called ivonescimab in 45 adults whose glioblastoma brain tumor has returned after standard treatment. Phase 1 finds the safest dose, and Phase 2 checks if that dose can control the tumor. The goal is to manage the disease, not cure it.

This study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…

This early-phase study tests a radioactive drug called 177Lu-PSMA-617 combined with standard chemotherapy (temozolomide) for people with aggressive IDH wild type gliomas. The goal is to see if the combination is safe and to get a first look at whether it helps control tumor growt…

This Phase II trial tests a bivalent vaccine (with an immune booster) plus two different schedules of oral β-glucan in 94 people with high-risk neuroblastoma who are in complete remission. The goal is to see which schedule triggers stronger antibodies against the cancer, potentia…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This study tests whether adding an experimental immune-boosting drug (N-803) to standard chemoimmunotherapy can help children and young adults whose neuroblastoma has returned or not responded to treatment. About 54 participants will receive the combination to see if it is safe a…

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…

This phase II trial tests a combination of four drugs—chidamide, dinutuximab beta, irinotecan, and temozolomide—in 27 children whose neuroblastoma has returned or not responded to standard treatment. The goal is to see how well the regimen controls the cancer and to monitor side …

This study tests a drug called FORE8394 (plixorafenib) in people aged 10 and older whose cancers have specific BRAF gene changes. The goal is to see if the drug can shrink tumors or slow their growth. About 254 participants with advanced solid tumors or brain tumors will take the…

This study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…

This pilot trial tests a portable, wearable device that delivers low-intensity magnetic therapy to people with newly diagnosed glioblastoma, an aggressive brain cancer. The study will enroll 30 adults who have had surgery and are able to receive standard radiotherapy. The main go…

This study tests whether adding the chemotherapy drug capecitabine to the standard temozolomide regimen can help people with newly diagnosed glioblastoma live longer without their tumor growing. About 67 adults who have completed initial radiation and chemo will take both pills a…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This study tests whether giving the drug bevacizumab (Avastin) directly into the brain's arteries, repeated over time, is safe and effective for people with recurrent glioblastoma or anaplastic astrocytoma. The approach uses a special infusion to bypass the blood-brain barrier. A…

This early study tests if a piece of belly tissue placed in the brain during surgery can safely bypass the blood-brain barrier in people with recurrent glioblastoma, an aggressive brain cancer. Ten adults will be followed for 6 months to check for side effects like rapid tumor gr…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…

This study tests a minimally invasive laser treatment for glioblastoma that regrows shortly after initial surgery, before standard radiotherapy and chemotherapy begin. The goal is to see if the laser can safely treat the regrowth without delaying the planned follow-up treatments.…

This phase III trial is testing whether delivering the drug bevacizumab (Avastin) directly to the brain through a catheter, along with standard chemo and radiation, can help people with newly diagnosed glioblastoma live longer. The study will enroll 432 adults with this aggressiv…

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This phase 2 trial tests enasidenib, a daily pill that targets the IDH2 gene mutation, in 40 adults with rare cancers of the nasal cavity or skull base that have spread or come back. Participants take the drug once daily in 28-day cycles, and researchers will track how long the c…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This study tests a new surgical technique for people with glioblastoma, an aggressive brain cancer. Surgeons place a piece of the patient's own tissue (from the scalp or skull lining) into the area where the tumor was removed. This tissue flap may help bypass the blood-brain barr…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study is for children whose solid tumors have returned or not responded to standard therapy. It combines an immunotherapy drug (atezolizumab) with three chemotherapy drugs to see if the mix is safe and can shrink tumors. About 23 children will take part, and the main goals a…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-phase trial tests a new biologic drug called SBO-154 in 177 people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink…

This early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's sid…

This trial tests a new way to treat glioblastoma, an aggressive brain cancer. The drug cetuximab, which blocks a protein that helps tumors grow, is infused directly into the brain's arteries after temporarily opening the blood-brain barrier. Up to 33 newly diagnosed patients will…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This study is testing a special type of proton radiation called PRDR for people whose fast-growing brain tumor (high-grade glioma) has come back after prior treatment. The goal is to see if this radiation can help control the tumor and improve survival while keeping side effects …

This study tests a radioactive drug called I-MIBG in people with resistant neuroblastoma or related tumors (pheochromocytoma and paraganglioma). The drug is designed to deliver radiation directly to cancer cells. Researchers want to see if it can shrink tumors and how safe it is.…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This early-phase trial tests a 28-day course of two oral drugs (mirdametinib and vorinostat) in people aged 12+ with a rare, aggressive nerve tumor linked to NF1. The goal is to see if the combination is safe and can shrink or change the tumor before standard treatment (radiation…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This early study tests whether adding the drug azeliragon to standard chemoradiotherapy can help the immune system fight glioblastoma, an aggressive brain cancer. About 12 adults with newly diagnosed glioblastoma will receive either standard treatment or standard treatment plus a…

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This study tests whether adding two different drug combinations after radiation can help children and young adults (up to age 21) with high-grade gliomas, including DIPG, live longer. One group receives ribociclib plus everolimus; another gets ribociclib plus temozolomide. The go…

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…

This Phase 3 trial tests whether adding a special radiation tile (GammaTile) during brain surgery improves survival for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 766 participants will be randomly assigned to standard treatment (surgery, radiatio…

This Phase 2 trial tests a two-part treatment for people with recurrent high-grade gliomas, a serious brain cancer. The treatment uses a virus (DB107-RRV) injected into the tumor and a chemotherapy pill (DB107-FC) taken by mouth. The goal is to shrink tumors and slow disease prog…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This study tests whether a new drug called TQ-B3234 can shrink non-surgical nerve tumors (plexiform neurofibromas) in adults with neurofibromatosis type 1 (NF1). About 177 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces tumor si…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This phase 2 trial tests whether a single injection of DNX-2401, a virus designed to kill cancer cells, can shrink or stabilize recurrent high-grade brain tumors in 39 children and young adults. Participants receive the virus directly into the tumor during a biopsy procedure. The…

This study tests two drugs—tarlatamab and temozolomide—in adolescents and adults with high-grade brain tumors that have a specific marker called DLL3. The goal is to see if the combination is safe and can shrink tumors. About 70 participants will be enrolled across multiple cente…

This early-stage trial is testing a personalized cell therapy for adults with recurrent oligodendroglioma, a type of brain tumor. The treatment involves taking a patient's own immune cells and stem cells, modifying them in the lab, and giving them back to fight the tumor. The mai…

This early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This early-stage trial tests a new therapy made from a patient's own immune cells, modified to better target and attack glioblastoma and other high-grade gliomas. The cells are designed to recognize a protein called CD70 found on these tumors. The main goals are to see if the tre…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This phase 3 trial tests whether the drug vorasidenib can delay tumor progression in people with IDH-mutant grade 2 or 3 astrocytoma after they finish initial chemoradiotherapy. About 468 participants will receive either vorasidenib or a placebo daily. The main goal is to see if …

This early-phase trial tests a new drug (rhIL-15) combined with three standard cancer drugs for children and young adults (ages 3–35) whose neuroblastoma did not respond to treatment or returned. The main goal is to find a safe dose and check for side effects. Up to 40 participan…

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-stage trial tests a new type of cell therapy for children whose embryonal tumors (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor) have returned or not responded to standard treatments. The therapy uses the patient's own immune cells, engineered to bette…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This early-stage trial is testing a new drug called Risvutatug rezetecan (Ris-Rez) in people with advanced solid tumors that have spread or cannot be removed. The study will give Ris-Rez alone or combined with other cancer drugs like chemotherapy or immunotherapy. Researchers wan…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This study is for children and young adults (ages 1 to 30) whose solid tumors have come back or not gone away with standard treatment. It tests two different drug pairs: one combines Onivyde with talazoparib, the other Onivyde with temozolomide. Both work by damaging cancer cell …

This early-stage trial is testing a new drug, QLS5212, in 100 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find …

This early-stage trial tests a precise type of proton radiation for children with ependymoma, a brain tumor. The therapy is designed to kill cancer cells while reducing damage to healthy brain tissue. About 48 children will take part to see if the treatment is safe and what side …

This phase 2 trial tests an oral drug called HLX-1502 in people aged 12 and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas—nerve tumors that can cause pain, disfigurement, or other problems. The study will enroll 25 participants and measure whether the…

This study tests whether a new drug called ivoximab, when combined with the chemotherapy temozolomide, is safe and effective for people with glioma that has returned or not responded to treatment. About 29 participants will receive the combination therapy, and doctors will check …

This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…

This study is for older adults (50+) with aggressive brain tumors (GBM) who are not healthy enough for surgery. It tests whether a shorter course of high-dose radiation, guided by a PET scan to target the most active tumor areas, can help them live longer compared to the current …

This study tests whether adding the drug selinexor to standard chemotherapy (temozolomide) can better control recurrent glioblastoma, an aggressive brain cancer. About 97 adults whose tumor has returned after initial treatment will receive either the combo or chemotherapy alone. …

This study tests whether giving a higher dose of radiation along with a drug called bevacizumab can help people with a fast-growing brain tumor (glioblastoma) live longer. About 146 adults aged 18 to 70 with a specific type of glioblastoma will receive the treatment. The goal is …

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…

This study tests whether adding the drug VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG) in adults. About 10 participants aged 18 to 75 will receive the combination treatment. The main goal is t…

This study tests a new drug called AZD1390 given alongside radiation therapy for children with aggressive brain tumors (high-grade glioma, DIPG, or DMG). The drug blocks cancer cells from repairing damage caused by radiation, potentially making treatment more effective. About 54 …

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…

This study tests a drug called PLX038 in adults with brain or spinal cord tumors, including those with changes in the MYC or MYCN genes. The trial has two phases: first, finding the right dose, then checking if it works. Participants receive PLX038 intravenously every three weeks…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This study tests a drug called mirdametinib for people with certain brain or spinal cord tumors (gliomas). The goal is to see if it is safe and can shrink tumors or improve symptoms. About 26 adults will take part, and the drug targets tumors with specific genetic changes.

This early-phase trial tests a new drug called SXRN, made from DNA, in 28 people with advanced solid tumors who have run out of standard options. The main goals are to check safety and find the right dose, while also seeing if it helps with appetite and physical function. The stu…

This study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…

This early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …

This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…

This early-stage study tests a new drug called SIGX1094R in about 102 adults with advanced solid tumors who have no standard treatment left. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also look at how food c…

This early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tu…

This trial tests a new approach for glioblastoma, an aggressive brain cancer. A device implanted in the skull uses ultrasound to temporarily open the blood-brain barrier, allowing immune-boosting drugs to reach the tumor. The study involves 25 adults who have completed radiation,…

This early-stage trial tests whether RNA-lipid particle vaccines can be safely made and given to adults with recurrent glioblastoma, an aggressive brain cancer. The vaccines are designed to teach the immune system to attack tumor cells. The study will enroll 24 participants and f…

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…

This trial tests an experimental drug, BGB-58067, in people with a newly diagnosed and aggressive brain cancer called glioblastoma. The drug is designed to work specifically in tumors missing a certain gene (MTAP). The study first checks if the drug reaches the brain and affects …

This study tests the drug entrectinib in children under 3 with certain brain tumors (NTRK or ROS1 gene fusions). The goal is to see if the drug can shrink tumors and delay the need for chemotherapy. About 52 children will take entrectinib by mouth, and doctors will monitor tumor …

This study tests an experimental drug called ACT001 in children and young adults (ages 1 to 39) with two aggressive brain tumors: DIPG and H3K27-altered high-grade gliomas. The goal is to see if ACT001 can improve survival or shrink tumors after radiation therapy. About 60 partic…

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This early-phase study tests a new treatment for a type of brain cancer (glioblastoma) that has come back after standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack the cancer. The main goal is to check the safet…

This early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. Th…

This study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…

This early-stage study tests whether a new treatment using a patient's own immune cells, engineered to attack two specific targets on glioblastoma cells, is safe. It involves 9 adults with a newly diagnosed, aggressive form of glioblastoma who have completed radiation but show no…

This Phase 2 trial is testing a vaccine called PEP-CMV in 120 children and young adults with high-grade glioma, diffuse intrinsic pontine glioma (DIPG), or recurrent medulloblastoma. The vaccine targets a common virus (CMV) found in many brain tumors, aiming to boost the immune s…

This early-stage trial tests a fluorescent dye called panitumumab-IRDye800 that attaches to cancer cells. Before surgery, 30 adults with brain tumors will receive a single infusion of the dye. During their operation, a special camera will detect the dye's glow, helping surgeons d…

This study tests a special dye that makes brain tumor cells glow under a camera during surgery. The goal is to help surgeons see and remove more of the tumor while sparing healthy brain tissue. About 46 adults with malignant glioma or vestibular schwannoma will receive the dye be…

This study tests whether a special PET scan using GA-68 PSMA-11 can tell the difference between a returning brain tumor and changes caused by previous treatment. About 25 adults with grade 3 or 4 glioma who are already scheduled for surgery will receive the scan beforehand. If su…

This pilot study is testing whether a special MRI dye called hyperpolarized pyruvate is safe and can help doctors see gliomas more clearly. About 140 adults with suspected or confirmed glioma will receive the dye and undergo MRI scans. The goal is to check for side effects and se…

This study is testing whether chemical marks on RNA molecules found in blood and urine can help diagnose gliomas, a type of brain tumor. Researchers will collect samples from 228 adults scheduled for brain surgery and compare them to healthy controls. The goal is to develop a non…

This study tests whether advanced MRI and CT scans can tell the difference between a brain tumor that is actually growing (true progression) and one that only looks like it is growing after treatment (pseudoprogression). About 25 adults who have had brain tumor treatment and now …

This study tests whether a special brain scan (PET-MRI) done within 48 hours after glioblastoma surgery is safe and practical. Fifteen adults who just had their first surgery for a suspected glioblastoma will get this scan, which uses a radioactive tracer and contrast dye. The go…

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…

This early-phase study tests a new type of PET/MRI scan that uses special radioactive tracers to detect leftover high grade glioma (a fast-growing brain cancer) after standard radiation therapy. About 20 patients aged 10 and older will receive up to three imaging sessions. The go…

This study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is …

This study tests a new type of PET/CT scan using a radioactive tracer called 68Ga-DOTATATE to see if it can detect neuroblastoma tumors better than the current standard scan (123I-MIBG). The study will enroll 20 children and young adults with suspected or confirmed neuroblastoma.…

This early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…

This study is testing a new blood test that looks for DNA from cancer cells. The goal is to see if an artificial intelligence program can accurately detect many different types of cancer at an early stage. The study will include 6,000 adults, some with cancer and some healthy vol…

This study tests a new technique called sonobiopsy that uses focused ultrasound to release DNA from brain tumors into the bloodstream, making it easier to detect and analyze the tumor's genetic makeup through a simple blood test. The goal is to improve diagnosis and treatment pla…

This study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test wo…

This early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where i…

This study tests whether giving selumetinib early to children with NF1, before nerve tumors cause symptoms, can prevent tumor growth and related problems. About 200 children aged 1 to 8 years with no known tumors will either receive the drug or be observed. The goal is to see if …

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses talk with patients about their personal values during routine cancer care. The goal is to make care more respectful and supportive. About 234 adults will take par…

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This study looks at whether virtual music therapy is practical and helpful for people recently diagnosed with glioblastoma, a serious brain cancer. Thirty-five participants will either join live music therapy sessions with a board-certified therapist or listen to curated playlist…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This pilot study looks at whether taking the chemotherapy drug temozolomide at a specific time of day (morning or evening) is practical for people with glioblastoma, a type of brain cancer. Fifty adults who have completed surgery and radiation will be randomly assigned to take th…

This study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…

This study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…

This study tests a new program called EASE, which uses a simple writing exercise to help adults with advanced cancer manage their fear of the future and related trauma symptoms. The study will include 250 people with advanced solid tumors, glioblastoma, or certain ovarian or lung…

This phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …

This study tests three ways to help adults with low-grade glioma improve memory and attention: an iPad app (ReMind), daily health text messages, and in-person cognitive rehab. About 97 participants will try one of these programs for several weeks, and researchers will track their…

This study tests whether proton beam radiation causes fewer side effects than standard photon radiation in people with glioblastoma, an aggressive brain cancer. About 326 patients will receive either proton or photon therapy alongside standard care. The main goal is to see if pro…

This study compares two painkillers given through a patient-controlled pump after brain surgery. The goal is to see if oliceridine causes less nausea than the standard drug sufentanil. 174 adults having surgery near the base of the skull will be randomly assigned to one of the tw…

This study looks at whether a culturally tailored Latin dance program can help Hispanic cancer survivors sleep better. Researchers will enroll 40 adults who have finished their main cancer treatment but still have trouble sleeping. Participants will either take dance classes or c…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests four different approaches—behavioral therapy, physical therapy, medication changes, and buprenorphine rotation—to help cancer survivors reduce their opioid use while keeping pain under control. It involves 294 veterans who have finished cancer treatment but still…

This study enrolls people with endocrine tumors (such as thyroid, parathyroid, adrenal, or pancreatic tumors) who are scheduled for surgery or biopsy. Researchers collect samples of the tumor, nearby healthy tissue, blood, and urine to analyze genetic and molecular changes. The g…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This early-phase trial tests a special version of the immunotherapy drug nivolumab that has a fluorescent dye attached (nivo800). The dye makes the drug glow under near-infrared light, allowing researchers to see exactly where the drug goes in the tumor during surgery. About 38 a…

This study is following children and adults with olfactory neuroblastoma, a rare cancer of the nasal cavity, to learn more about how the disease behaves over time. Researchers will collect medical records, blood samples, and survey responses from 525 participants to track symptom…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This study explores whether a computer algorithm can analyze resting-state MRI scans taken before surgery to predict how long a person with glioblastoma multiforme (a type of brain cancer) might survive. The goal is to see if the algorithm can accurately classify patients as shor…

This study creates a registry of medical records, scans, and surveys from adults with neurofibromatosis type 1 (NF1) who also have a glioma brain tumor. Researchers will track diagnosis, treatments, and quality of life over time to better understand the disease. The goal is to im…

This study looks at whether recording electrical activity in and around high-grade glioma tumors during surgery can help predict how the tumor will progress. Ten adults with suspected or confirmed high-grade glioma will undergo standard surgery plus extra brain recordings and a s…

This study collects information from 200 adults in Russia who have neurofibromatosis type 1 (NF1) with plexiform neurofibromas. Researchers will look at patients' age, symptoms, and medical history to better understand the disease. No new treatments are being tested; the goal is …

This early-phase trial will test how Acetadote, a drug that affects cell damage, changes metabolism in people with newly diagnosed glioblastoma. Ten participants will receive Acetadote before surgery, and researchers will use MRI scans and tumor tissue analysis to measure metabol…

This study collects blood and urine samples from 200 adults with glioblastoma (a type of brain tumor) who are receiving radiation therapy. Researchers want to see if levels of two proteins, VEGF and MMP, can predict whether the tumor will come back within one year. The goal is to…

This study follows 269 people with neurofibromatosis type 2 (NF2) for up to 10 years to learn how the disease progresses. Participants will have yearly exams, MRI scans, hearing tests, and blood draws. The goal is to understand tumor growth, hearing loss, and speech or swallowing…

This study looks at whether a program called 'Couples Coping Together Against Cancer' is helpful and practical for people with advanced cancers like stage IV breast cancer, glioblastoma, or lung cancer, and their partners. Researchers at City of Hope will enroll 160 couples to se…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study works to improve questionnaires that measure pain, daily activities, and physical function for people with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas. Participants aged 5 and older will give feedback on existing surveys through group discussions or…

This phase II trial is testing whether advanced imaging techniques like DSC-MRI and PET scans can better distinguish actual tumor growth from treatment-related changes in people with newly diagnosed glioblastoma. The study will enroll 100 adults who are receiving standard treatme…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study follows about 50,000 people who survived childhood cancer (diagnosed before age 21 between 1970 and 1999) and 10,000 of their siblings. Researchers want to understand how cancer treatments like radiation, chemotherapy, and surgery affect health years later. By comparin…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study follows 300 adults with primary brain tumors (such as glioma or meningioma) who are receiving partial brain radiation. Researchers use brain scans and memory, attention, and language tests before and after treatment to understand how radiation affects thinking skills. …

This early-stage trial is testing whether the drug ulixertinib can cross the blood-brain barrier in people with recurrent brain tumors called gliomas. About 40 adults will take the drug before surgery to see how much reaches the tumor and how safe it is. The goal is to learn if t…

This study uses genetic testing of brain tumors from children, adolescents, and young adults (ages 1 to 39) with newly diagnosed high-grade glioma, including DIPG. The goal is to identify specific genetic changes in each tumor and then see if patients can join a treatment trial t…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study is testing a device called the AlgometRx Nociometer to see if it can measure pain and other abnormal sensations in people with neurofibromatosis type 1 (NF1). The device uses a small electrode on a finger or toe to send painless signals and a camera to record changes i…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study collects blood or apheresis samples from 24 people with solid tumors and healthy volunteers. Researchers will analyze immune cells to see how they respond to a neoantigen vaccine, which is designed to help the immune system recognize cancer. The goal is to learn how to…

This study looks at low-grade gliomas, a slow-growing type of brain tumor, in Argentina. Researchers will review medical records from about 40 patients to find out how common these tumors are and how long people live after diagnosis. The goal is to better understand these tumors …

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study is testing a new approach to personalize treatment for people with a fast-growing brain tumor called glioblastoma. Researchers will use a lab test on tumor cells to see which drugs might work best for each patient. The goal is to find out if this method can help more p…

This study is for people aged 3 and older with neurofibromatosis type 1 (NF1), a genetic condition that often causes noncancerous nerve tumors. About half of people with NF1 get these tumors, and sometimes they turn cancerous. Researchers want to test a new method to predict whic…

This study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…

This study tests a new communication tool called 'Let's Get REAL' that helps children and teens (ages 8-17) and their families talk together about stem cell transplant or cellular therapy decisions. The goal is to see if the tool is easy to use and helpful for families. About 60 …

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…

This study looks at three small molecules (miRNAs) that may help stop glioma, a type of brain tumor, from growing and spreading. Researchers will test these molecules in cells from 10 patients to see how they affect tumor behavior and response to standard treatments like radiatio…

This study looks back at data from 370 children treated for ependymoma, a common brain tumor in kids. Even after surgery and radiation, about half of these tumors return. Researchers are using artificial intelligence to analyze medical images, genetics, and treatment records to f…

This study tests a special pair of glasses (loupe-based device) that helps surgeons see brain tumor tissue during surgery using fluorescence. The goal is to see if this wearable device is as accurate as the large microscope currently used. 30 adults with glioblastoma or anaplasti…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This early-stage trial tests a new device called the CIPHER System, which records brain activity during surgery to remove a type of brain tumor called glioma. Ten adults with newly diagnosed glioma will have the device placed on their brain surface during standard tumor removal. …

This study tracks how brain areas controlling movement, language, and sensation change during glioma treatment. Twenty patients with brain tumors will undergo repeated MRI scans as part of their regular care. Researchers aim to understand the brain's ability to adapt over time, w…

This study is testing whether an artificial intelligence (AI) model can accurately predict the molecular subtype of midline gliomas (a type of brain tumor) using MRI scans taken before surgery. Researchers will compare the AI's predictions with standard lab tests after surgery to…

This study is testing a new technology called SmartMatch that analyzes tumor tissue from people with recurrent brain or spinal cord tumors. The goal is to see if SmartMatch can quickly identify which drugs might work best for each person's specific tumor. About 80 participants ag…

This study watches 200 adults having brain tumor surgery to see how often cerebrospinal fluid leaks happen and what makes them more likely. The goal is to find ways to prevent leaks and help people recover faster. No new treatment is being tested—just careful observation.

This study is testing whether special MRI scans can identify low-oxygen (hypoxic) areas in glioblastoma, an aggressive brain cancer. Researchers will compare these scans with a standard PET imaging method in 20 participants. The goal is to see if MRI can reliably guide radiation …

This study compares two common methods of closing the skin after brain tumor surgery: a continuous stitch under the skin using absorbable thread versus separate stitches through the skin using non-absorbable thread. Researchers want to see which method leads to fewer wound proble…

This study tracks mental health and suicide risk in 176 adults with glioblastoma, a serious brain cancer. Participants fill out questionnaires about depression, anxiety, quality of life, and suicidal thoughts. The goal is to understand what factors increase suicide risk in these …

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…